AARTIPHARM — Aarti Pharmalabs Balance Sheet
0.000.00%
- IN₹75.57bn
- IN₹79.16bn
- IN₹21.15bn
- 73
- 21
- 72
- 59
Annual balance sheet for Aarti Pharmalabs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | Interim Report | ARS | ARS | ARS |
| Standards: | — | — | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2.5 | 1,603 | 990 | 1,007 | 556 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | 3,882 | 4,524 | 5,893 | 6,570 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2.5 | 10,281 | 11,558 | 13,456 | 13,222 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0 | 9,453 | 9,861 | 10,932 | 14,107 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2.5 | 20,399 | 22,309 | 25,821 | 29,064 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.219 | 5,807 | 5,916 | 6,944 | 6,570 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 0.219 | 6,534 | 6,724 | 8,251 | 9,165 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 2.28 | 13,865 | 15,585 | 17,570 | 19,899 |
| Total Liabilities & Shareholders' Equity | 2.5 | 20,399 | 22,309 | 25,821 | 29,064 |
| Total Common Shares Outstanding |